AMG 509 for advanced, hormone-resistant prostate cancer
Treatments studied
Part of Cancer, Injuries & trauma, Kidney & urinary clinical trials.
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer confirmed by biopsy (adenocarcinoma, not small cell/neuroendocrine).
- Your cancer is still progressing despite ongoing testosterone-lowering treatment (orchiectomy or continuous GnRH therapy) and your testosterone is very low.
- Your prior treatments fit the trial’s specific pattern: limited numbers of hormone tablets and limited taxane (docetaxel-type) chemotherapy, with some parts allowing only fewer prior treatments.
- You can’t have certain recent therapies or conditions, like untreated brain/spine metastases, recent major surgery, or anti-cancer treatment within 4 weeks.
- Your heart, kidneys, liver, lungs, and blood counts must be within safe ranges, and you should be well enough to do daily activities (performance status 0–1).
- If you join the “retreatment” part, you must have previously benefited from AMG 509 and agree to a new tumor biopsy before starting again.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.